Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06399757 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
A Phase 1 study of Prostate Cancer and Colorectal Cancer, sponsored by Apollo Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 9
- Study locations
NCT06399757: Recruiting Phase 1 study of Prostate Cancer and Colorectal Cancer, sponsored by Apollo Therapeutics.
NCT06399757 is a Phase 1 study of Prostate Cancer and Colorectal Cancer that is actively recruiting participants, run by Apollo Therapeutics. The registered enrollment target is 100 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (84% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06399757, a Phase 1 study of Prostate Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Apollo Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
Primary Outcome
Evaluation of safety parameters including treatment emergent adverse events as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, electrocardiogram results.
Conditions Studied
Interventions
- DRUG APL-5125
Study Locations (9)
California
- City of Hope - Duarte
- City of Hope Orange County Lennar Foundation Cancer Center - Irvine
North Carolina
- Duke Cancer Institute - Durham
- Carolina BioOncology Institute - Huntersville
Texas
- Mary Crowley Cancer Research - Dallas
- NEXT Oncology- San Antonio - San Antonio
Florida
- Florida Cancer Specialists & Research Institute - Sarasota
Michigan
- University of Michigan - Ann Arbor
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-06-18 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
What NCT06399757 shows while recruiting
NCT06399757 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (84% lower).
The record links to 9 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which APL-5125 is the first listed.
NCT06399757 lists 9 locations in 6 states (California, North Carolina, Texas).
Frequently Asked Questions
What is clinical trial NCT06399757 about?
NCT06399757 is a clinical study titled "A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors". This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
What is the current status of trial NCT06399757?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-06-18. Estimated completion is 2027-05.
What conditions does trial NCT06399757 study?
This clinical trial studies the following conditions: Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT06399757?
The interventions under investigation include: APL-5125 (DRUG).
Who is sponsoring clinical trial NCT06399757?
This trial is sponsored by Apollo Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06399757 being conducted?
This trial has 9 study locations across California, Florida, Michigan, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06399757's enrollment target sits among peer trials
100 330th of 735 higher than 389 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI